Skip to main content

CRD3874-SI (STING Agonist)

CRD3874-SI in People With Leukemia

  • RegistryNCT07661095
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRelapsed or Refractory Acute Myeloid Leukemia
  • SponsorMemorial Sloan Kettering Cancer Center
How CRD3874-SI worksNCT076610951 min

What the film says

Read the transcript

This trial is for adults with acute myeloid leukemia that has come back or not responded to treatment.

The idea: CRD3874-SI is a STING agonist. STING, short for stimulator of interferon genes, is an alarm switch inside cells. Turning it on may push the immune system to attack the leukemia.

The study looks at whether CRD3874-SI is safe.

This phase 1 study plans 24 patients. At Memorial Sloan Kettering Cancer Center in New York, Eytan Stein leads it.

Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

CRD3874-SI is a STING (Stimulator of Interferon Genes) agonist in participants with relapsed and refractory (R/R) acute myeloid leukemia (AML).

The study

How the trial runs.

The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Documentation of Disease
  • o Participant has relapsed or refractory acute myeloid leukemia, defined as bone marrow blasts ≥ 5%, and/or reappearance of blasts in the blood in at least 2 peripheral blood samples at least one week apart, and/or development of extramedullary disease; or, no CR, CRh or CRi at response assessment after at least 1 line of therapy, as defined by standardized European LeukemiaNet 2022 Criteria. Patients must have failed treatment with available therapies known to be active for treatment of their AML.
  • Participant must be ≥ 18 years of age at the time of signing the informed consent form (ICF).
  • Participant must weigh at least 40 kg
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 (See Appendix I for performance status criteria)

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.